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Patient- Focused Drug Development Methods 
for Benefit–Risk Assessments: A Case Study 
Using a Discrete Choice Experiment for 
Antiepileptic Drugs 
Emily A.F. Holmes1, Catrin Plumpton1, Gus A. Baker2, Ann Jacoby3, Adele Ring4, Paula Williamson5, 
Anthony Marson2,6 and Dyfrig A. Hughes1,2
Regulatory decisions may be enhanced by incorporating patient preferences for drug benefit and harms. This study 
demonstrates a method of weighting clinical evidence by patients’ benefit–risk preferences. Preference weights, 
derived from discrete choice experiments, were applied to clinical trial data to estimate the expected utility of 
alternative drugs. In a case study, the rank ordering of antiepileptic drugs (AEDs), as indicated from clinical studies, was 
compared with ordering based on weighting clinical evidence by patients’ preferences. A statistically significant change 
in rank ordering of AEDs was observed for women of childbearing potential who were prescribed monotherapy for 
generalized or unclassified epilepsy. Rank ordering inferred from trial data, valproate > topiramate > lamotrigine, was 
reversed. Modeling the expected utility of drugs might address the need to use more systematic, methodologically 
sound approaches to collect patient input that can further inform regulatory decision making.
Drug development and regulatory decision making require ex-
plicit evaluation of benefits and risks. In balancing the benefits 
and risks of drugs, judgements are required on the maximum 
acceptable risk (MAR) of harm for an expected health benefit. 
Traditionally, these judgements have relied on expert clinical 
opinion of the available evidence. More recently, however, there 
is increasing acknowledgment that patients’ preferences with re-
spect to trade- offs in harms for benefits may differ from those of 
clinical experts and that patient perspectives need to be considered 
in benefit–risk assessments.1,2
The US Food and Drug Administration (FDA) Center for 
Drug Evaluation and Research currently implements a qualitative 
approach via the Patient- Focused Drug Development Program 
under the fifth and sixth authorizations of the Prescription Drug 
User Fee Act. This involves patients in the approvals process by 
convening public meetings to discuss the impact of disease on 
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WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Discrete choice experiments have been recognized as a suita-
ble method for eliciting evidence on patients’ preferences to in-
form regulatory benefit–risk assessments.
WHAT QUESTION DID THIS STUDY ADDRESS?
 What is the impact of weighting clinical evidence by patients’ 
benefit–risk preferences, and how can this be achieved in 
practice?
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
 On the basis of a case study of antiepileptic drugs (AEDs), 
patients were willing to accept a reduction in the chance of 
seizure remission in exchange for a reduction in the risk of ad-
verse effects. This resulted in changes to the trial- based rank or-
dering of AEDs, determined from time to treatment failure.
HOW MIGHT THIS CHANGE CLINICAL 
PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
 Explicit consideration of patient preferences could lead to 
different conclusions relating to the benefit–risk profiles of med-
icines. This has implications for drug development and regula-
tion, in how patient values and clinical attributes may be 
integrated to inform benefit–risk assessments.
Study Highlights
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patients’ daily lives and patients’ perspectives on treatment benefits 
and adequacy.3 The European Medicines Agency’s Committee for 
Medicinal Products for Human Use piloted patient involvement 
in benefit–risk discussions through their participation in expert 
group meetings and the scientific advice/protocol assistance pro-
cedure.4 The Committee for Medicinal Products for Human Use 
continues to involve patients in oral explanations when it is be-
lieved this could be of benefit. The FDA’s Center for Devices and 
Radiological Health (CDRH), by contrast, has adopted a more 
quantitative approach and considers evidence relating to patients’ 
perspectives of what constitutes meaningful benefit–risk.2,5
Moving forward, the 21st Century Cures Act (section 3002) re-
quires the FDA to develop guidance (by quarter 4 2021) for inte-
grating relevant patient experience data in benefit–risk assessments 
for new drugs and biological agents.6 Although specific details are 
currently unknown, it is worth noting the CDRH’s guidance in-
cludes 11 recommendations for the conduct of quantitative patient 
preference studies,5,7 and a project coordinated by the European 
Medicines Agency outlined a range of methods.8 Both organiza-
tions identify discrete choice experiments (DCEs) among poten-
tial options for use in benefit–risk assessments of medicines.
Stated preference DCEs are a method for quantifying the rela-
tive importance of different treatment characteristics (attributes), 
trade- offs between these attributes, and respondents’ total satis-
faction (utility) with specified treatments.9 The method has been 
used extensively for the evaluation of health services and health 
technologies,10,11 and there is increasing application in the deter-
mination of benefit–risk trade- off for medicines.12,13 In DCEs, 
respondents are asked to choose their preferred option from a set 
of hypothetical (but realistic) alternatives, on the basis of attributes 
and their respective levels determined using established qualitative 
methods.14
Modeling the expected utility of drugs, on the basis of patient- 
defined benefit–risk trade- offs, offers a quantitative approach to 
inform drug development and regulatory decision making. The 
present study demonstrates the potential for the DCE method in 
benefit–risk assessment. Patient priorities for drug outcomes are 
first identified using qualitative interviews and ranking exercises. 
Patient preferences for the most important outcomes are then 
valued using a DCE. This generates preference weights for each 
selected outcome that are applied to observed data from a clinical 
trial. The expected utilities of alternative drugs are then modeled 
to generate patient- defined benefit–risk preferences for a selection 
of alternative drugs.
The case study is based on antiepileptic drugs (AEDs), selected 
because of the particular need to balance benefits against the risks 
of harm.15 Although two thirds of patients treated with AEDs will 
achieve remission from seizures within 5 years of diagnosis, at least 
40% of patients will experience treatment- related adverse effects.16,17 
Patient- determined levels of acceptable harm for improved seizure 
control are rarely considered in clinical trials.18 However, they 
are essential considerations, especially for women of childbearing 
potential with generalized epilepsy, in whom choices need to 
be made between the most effective yet teratogenic treatment, 
valproate, and less teratogenic (but less effective) alternatives.17,19 In 
this case study, we aimed to compare patient- defined benefit–risk 
preferences with the results of a clinical trial of AEDs16,17 and to 
assess differences between patient subgroups.
RESULTS
Benefit and risk attribute selection
Fifty- four patients and nine physicians (34% and 90% of those in-
vited, respectively) participated in the qualitative study to identify 
the most important benefit and risk outcomes for use in the DCE. 
Reduction in seizure frequency was the most important treatment 
outcome (benefit) across all groups (Table S1), and discussions sur-
rounding this outcome focused on seizures stopping and patients 
achieving remission. The importance of adverse effects (risks) var-
ied by patient group: recently diagnosed patients were most con-
cerned about feelings of aggression and depression, whereas those 
with an established diagnosis were most concerned about memory 
problems. Women of childbearing potential also ranked memory 
problems highest, followed by the risk of fetal abnormality if they 
became pregnant while taking the drug. Physicians ranked mem-
ory problems and depression highly. Patients and physicians val-
ued life impacts (e.g., reduced independence), but in the context of 
the decision to initiate or switch an AED, physicians considered 
them to be consequences of epilepsy, or the adverse events (AEs) of 
treatment, rather than independent treatment outcomes. As such, 
they were excluded from the DCE. Attributes selected for the 
DCE are presented in Table 1. Two versions of the DCE were de-
veloped to represent the most important attributes selected by pa-
tients with a recent or established diagnosis (DCE- 1) and women 
of childbearing potential (DCE- 2) (Figure S1).
Discrete choice experiment
Among those who consented to the survey, 4 withdrew before ran-
domization and 29 did not start their DCE, leaving 280 patients 
for this analysis (Table 2).
All patients preferred the AED offering the greatest benefits and 
the lowest risk of harm, as indicated by direction of the signs on 
the coefficients (+/−) (Table 3). Patients had stronger preferences 
for reductions in the risk of AEs than improvements in 12- month 
seizure remission, as shown by the greater magnitude of the harm 
coefficients. Experiencing fewer seizures did not have a significant 
influence on AED preferences of women of childbearing potential 
(P = 0.685).
The maximum acceptable increase in risks of adverse effects for 
an AED that increases the chance of 12- month remission by 10% 
(in DCE- 1) were as follows: 3.1% for depression, 3.0% for memory 
problems, and 2.5% for aggression. For women of childbearing po-
tential, the MAR of fetal abnormality was 2.0% for a 10% increase 
in probability of remission, compared with 5.6% for depression 
and 3.4% for memory problems.
Patient utility associated with selected AEDs
The preference- weighted outcomes (remission, reduction, mem-
ory problems, depression, aggression/fetal abnormality) for four 
alternative drugs for focal epilepsy (carbamazepine, lamotrigine, 
gabapentin, and topiramate) and three alternative drugs for gener-
alized and unclassified epilepsy (valproate, lamotrigine, and topi-
ramate)16,17 are displayed in Figure 1. On the basis of total utility 
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(sum of the weighted outcomes), respondents to DCE- 1 indicated 
carbamazepine would be the most preferred AED for focal epi-
lepsy, and topiramate the least. The disutility associated with topi-
ramate (−0.67) suggests these patients would prefer to avoid it. For 
generalized or unclassified epilepsy, valproate yielded higher util-
ity than both lamotrigine and topiramate. In both cases, ranking 
based on utility differed from ranking based on time to treatment 
failure, as observed in clinical trials (Figure 1a); however, this did 
not reach statistical significance.
Women of childbearing potential responding to DCE- 2 favored 
lamotrigine over carbamazepine for focal epilepsy, in agreement 
with trial- based ranking; however, gabapentin ranked second when 
the trial outcomes were weighted in the utility model. Topiramate 
was associated with the lowest utility. Lamotrigine was also favored 
for generalized or unclassified epilepsy, with valproate being the 
least preferred; thus, weighting by patient preferences for benefit 
and harm outcomes resulted in a statistically significant reversal 
of rankings.20 The combined risk and preference weighting for 
fetal abnormality heavily influenced the disutility of valproate 
(Figure 1b).
The improvement in benefit associated with a switch to val-
proate did not outweigh the increase in risk for women of child-
bearing potential. A switch from topiramate to valproate for 
generalized or unclassified epilepsy, for instance, increased the risk 
of fetal abnormality by 6.65%,19 which exceeds the 1.41% MAR 
that corresponds to the 7% improvement in 12- month remission 
seen with valproate17 (Table S2).
DISCUSSION
DCEs represent a valid and reliable method to quantify patient- 
focused outcomes.10–13 The utility model demonstrated how 
quantitative data on patient preferences can be integrated with 
clinical evidence to provide a patient- focused benefit–risk analy-
sis that could be used to inform regulatory decision making. The 
case study illustrates how DCEs can provide an explicit estimate 
of patient- defined MAR, which may differ from value judgements 
based on clinical evidence alone.
The FDA implemented changes after the fifth authorization of 
the Prescription Drug User Fee Act, to increase the clarity, trans-
parency, and consistency of its benefit–risk assessments. With the 
passage of the 21st Century Cures Act, the FDA now has an imper-
ative to consider how relevant patient experience data and related 
information can be incorporated into the structured benefit–risk 
assessment framework to inform regulatory decision making.6 Our 
proposed method is one approach that might address the FDA’s 
recognized need to use more systematic, methodologically sound 
approaches to collect patient input so that it becomes data that can 
further inform regulatory decision making21 (Figure 2).
Table 1 Attributes and levels of the discrete choice experiment
DCE attributea DCE levels (coding) Level selection Description (before choice questions)
Seizures stop
One year after starting this 
medication
5 in 10 people (0.5) 
3 in 10 people (0.3)
Plausible estimates based on:
• Seizure frequency16,17
• Clinical expert opinion (research 
team, scientific advisory group, 
and group discussion meeting 
with prescribing physicians)
We would like you to imagine you have 
the choice between two medications: 
medication A and medication B. We will 
give you the same information about 
each medication. 
The chance of responding well: 
- Seizures stop 
- Fewer seizures
Fewer seizures
One year after starting this 
medication
3 in 10 people (0.3) 
1 in 10 people (0.1)
Memory problems
These problems frequently 
affect activities of daily life
1 in 100 people (0.01) 
7 in 100 people (0.07)
Plausible estimates based on:
• Clinically important adverse 
events and patient-reported 
quality of life outcomes16,17
• Section 4.8 of the summary of 
product characteristics of AEDs 
used in the SANAD trial16,17
• Clinical expert opinion (research 
team, scientific advisory group, 
and group discussion meeting 
with prescribing physicians)
The risk of severe adverse effects. 
- Memory problems 
- Depression 
- Feelings of aggressionb
These adverse effectsc would be so 
severe that you would need to change to 
a different antiepileptic medication
Depression
A feeling of low mood that 
often affects activities of 
daily life
1 in 100 people (0.01) 
8 in 100 people (0.08)
Feelings of aggressionb
This can be verbal or 
physical and often affects 
relationships and activities 
of daily life
1 in 100 people (0.01) 
8 in 100 people (0.08)
Harm to your fetus if you 
get pregnant while taking 
this medicationd
Causing problems from 
birth, such as spina bifida 
or low IQ
2 in 100 pregnant 
women (0.02) 
9 in 100 pregnant 
women (0.09)
Minimum and maximum risk of 
AED- related fetal abnormality 
reported to patients via the Epilepsy 
Action charity website at the time of 
the survey.
Finally, we will also give you information 
on the risk of harm to the fetus if you get 
pregnant while taking this medication. 
This may cause problems, such as spina 
bifida, a hole in the heart, and a cleft 
palate (where the roof of the mouth is not 
correctly joined). This may also cause 
neurodevelopment problems, such as 
poor memory, poor language and social 
skills, and low IQ.
AED, antiepileptic drug; DCE, discrete choice experiment; IQ, intelligence quotient; SANAD, Standard vs. New Antiepileptic Drugs. aAs described in each of the 
eight choice questions. bOnly in DCE for patients with a recent or established diagnosis. cTerm “adverse effects” used to describe adverse events, as per findings 
of our qualitative study. dOnly in DCE for women of childbearing potential.
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Patients have an important role alongside all other stakeholders 
in determining relevant outcomes and priorities, acceptable uncer-
tainty, as well as benefit–risk and value of a medicine.1,2 However, 
patients believe that decision makers, particularly regulators, do 
not always have a complete understanding of the risks that patients 
with some illnesses are willing to accept, and that this benefit–risk 
assessment will vary by disease.22 Our DCE- based approach linked 
with clinical trial evidence addresses this, by generating patient- 
defined benefit–risk thresholds for drugs for specific clinical 
indications.
There are several examples of what could be interpreted as dif-
ferent levels of acceptance of risk among some patients, regulators, 
or other stakeholders–most notably, in the context of HIV, where 
“patient experts” successfully challenged the drug development and 
licensing paradigms, leading up to the FDA’s Accelerated Approval 
pathway. The antiparkinsonian drug, tolcapone, was marketed 
in the European Union in 1997, but cases of fatal hepatotoxicity 
led to its marketing authorization being suspended the following 
year.23 Patients and physicians argued that some patients experi-
ence improved quality of life and pleaded to gain access to the drug 
Table 2 Patient characteristics
Characteristics
DCE- 1 (N = 177) DCE- 2 (N = 103)
Excluding women of childbearing potential Women of childbearing potential
n/N % or rangea n/N % or rangea
Demographics
Age, median, yearsb 45 18–79 29 18–55
Female sex 95/177 54 103/103 100
White British 140/149 94 84/86 98
Live alone 28/149 19 6/87 7
Employed 76/149 51 69/87 79
Time since diagnosis, years
<1 9/176 5 3/103 3
1–10 40/176 23 40/103 39
>10 127/176 72 60/103 58
Seizure types
Focal 56/157 36 40/96 42
Complex focal 70/157 45 45/96 47
Absences 64/157 41 46/96 48
Tonic clonic 102/157 65 73/96 76
Time since last seizure (<1 month) 88/159 56 48/95 51
Seizure frequency compared with 1 year ago
Increased 39/157 25 17/96 18
Constant 69/157 44 48/96 50
Decreased 49/157 31 31/96 32
Change to antiepileptic medication (changes 
in past 3 months)
66/151 44 43/93 46
Change reason seizures 43/65 66 31/42 74
Change reason adverse effects 19/65 29 15/42 36
Change reason remission 5/65 8 2/42 5
Self- reported nonadherence to antiepileptic 
medicationc
37/66 56 24/42 57
Experience of adverse effects
Aggressionc 15/66 23 11/42 26
Depressionc 15/66 23 16/42 38
Memory problemsc 22/66 33 14/42 33
Change antiepileptic medication because of 
pregnancy concern
NA NA 31/97 32
DCE- 1, discrete choice experiment for patients with a recent or established diagnosis; DCE- 2, DCE for women of childbearing potential; NA, not applicable. 
aPercentage of eligible responses (excluding missing data). bN = 177 (DCE- 1), N = 103 (DCE- 2). cNumber restricted to patients who reported a change in the type 
or amount of antiepileptic drug in the past 3 months, because of a routing error in the online survey.
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while explicitly accepting the risk of hepatotoxicity. Their lobbying 
led to the lifting of the suspension in 2004. Both natalizumab (for 
patients with relapsing forms of multiple sclerosis) and alosetron 
(for irritable bowel syndrome) were voluntarily withdrawn by their 
manufacturers because of safety concerns.23 However, the FDA 
recommended their reintroduction to the market at the request of 
patients and family members. The use of methods to support reg-
ulatory benefit-risk assessments that consider patient preferences 
explicitly might have lessened the likelihood of misaligned prefer-
ences between the various stakeholders. Benefit–risk assessments 
are a qualitative exercise grounded in quantitative evidence, but 
just because patient perspectives are subjective does not mean that 
they cannot be quantified and analyzed accordingly.
Our case study showed that although seizure freedom was 
ranked the most important treatment outcome by patients during 
qualitative interviews, patients also prioritized reduction in the risk 
of adverse effects, and the importance of these effects differed by 
patient subgroup. The results of the DCE, however, suggest that 
patients are willing to accept a reduction in the chance of remis-
sion in exchange for a reduction in the risk of adverse effects—and 
that they attach a higher value on improving risk reduction than 
benefit. Women of childbearing potential would accept 5% reduc-
tion in the probability of 12- month remission to reduce the risk of 
fetal abnormality by 1%. The potential for our method to identify 
both MAR, and willingness to forego benefit, is particularly im-
portant with respect to prescribing valproate, which is considered 
the most effective treatment for certain epilepsy syndromes, such as 
juvenile myoclonic epilepsy, but is associated with the highest risk 
of teratogenicity.24
This study provides quantitative evidence on women’s strength 
of preference to avoid valproate, which aligns with recent advice 
from regulatory authorities.25–27 Understanding the balance be-
tween benefit and harm, and the extent to which women are will-
ing to forego benefit for this reduction in harm, could assist in the 
development of recommendations of alternative treatments to val-
proate and inform parameters of equivalence for new drugs.
We are aware of previous use of DCE to elicit preferences for 
AEDs.28–31 Lloyd et al.28 found that UK patients were willing to 
forego 4.85% seizure control for a 1% reduction in risk of hair loss, 
4.45% seizure control for a 1% reduction in risk of skin rash, and 
1.37% seizure control for a 1- lb (0.45- kg) reduction in weight gain. 
Manjunath et al.29 measured US patient preferences for add- on 
AEDs in terms of seizure frequency and AEs; and they found 
that seizure reduction was the top priority when ranked against 
the reduction or elimination of AEs. Powell et al.30 compared pa-
tients’ and neurologists’ preferences for a carbamazepine pharma-
cogenetic testing service. Ettinger et al.31 also conducted a DCE 
in patients and neurologists, and they found that, although both 
ranked seizure control most important, neurologists’ preferences 
were more influenced by seizure reduction compared with adverse 
effects for patients. None of these studies, however, assessed pref-
erences in the context of trial data pertaining to actual AEDs; in 
fact, we are unaware of any other studies that integrate benefit–risk 
preference weights, estimated using DCE methods, and trial data.
Table 3 Results of the DCE random- effects logistic regression model
Attribute
DCE- 1: excluding women of childbearing potentiala DCE- 2: women of childbearing potentiala
Coefficient (95% CI)b P value
Maximum 
 acceptable 
 incremental risk 
(%) per 1% increase 
in 12- month 
remission (95% CI)b Coefficient (95% CI)b P value
Maximum 
acceptable 
incremental risk (%) 
per 1% increase in 
12- month remission 
(95% CI)b
Remission 0.03 (0.03 to 0.05) <0.001 NA 0.05 (0.04 to 0.07) <0.001 NA
Fewer seizures 0.01 (0.00 to 0.02) 0.010 NA −0.00 (−0.01 to 0.01) 0.685 NA
Depression −0.11 (−0.15 to −0.10) <0.001 0.31 (0.24 to 0.39) −0.08 (−0.13 to −0.06) <0.001 0.56 (0.38 to 0.88)
Memory problems −0.11 (−0.16 to −0.10) <0.001 0.30 (0.23 to 0.40) −0.14 (−0.21 to −0.11) <0.001 0.34 (0.26 to 0.45)
Aggression/fetal 
abnormality
−0.13 (−0.18 to −0.13) <0.001 0.25 (0.20 to 0.31) −0.23 (−0.32 to −0.21) <0.001 0.20 (0.16 to 0.24)
Constant 0.03 (−0.19 to 0.12) 0.689 NA 0.47 (0.25 to 0.92) <0.001 NA
Number of 
observations
1,339 790
Number of groups 177 103
Wald χ2 (5 
degrees of 
freedom)
321.27 154.55
Log likelihood −674.71 −360.77
Pseudo R2 0.27 0.34
P value <0.000 <0.000
CI, confidence interval; DCE, discrete choice experiment; DCE- 1, DCE for patients with a recent or established diagnosis; DCE- 2, DCE for women of childbearing 
potential; NA, not applicable. aA total of 159 respondents to DCE- 1 (90%) and 97 respondents to DCE- 2 (94%) passed the dominance check question included for 
internal validity, by selecting the antiepileptic drug aligned with a priori expectations and thus indicating they comprehended the task. A model excluding 
respondents who failed the dominance check for internal validity did not differ significantly. bCIs generated by 1000 bootstrap replications.
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Figure 1 AED, antiepileptic drug; DCE- 1, discrete choice experiment for patients with a recent or established diagnosis; DCE- 2, DCE for women 
of childbearing potential. Preference- weighted outcomes of AEDs by DCE- 1 (a) and DCE- 2 (b). *High utility is most preferred. AEDs presented in 
order of highest to lowest utility, left to right by indication. **Clinical rank based on primary outcome in Standard vs. New Antiepileptic Drugs 
(SANAD) I (time to treatment failure). Rank 1 = high (i.e., longest time to treatment failure).
carbamazepine lamotrigine gabapenn tompiramate valproate lamotrigine topiramate
Remission 1.46 1.46 1.16 1.26 1.82 1.52 1.59
Seizure reducon 0.12 0.19 0.13 0.09 0.11 0.14 0.05
Depression –0.24 –0.39 –0.30 –0.73 –0.05 –0.29 –0.10
Memory problems –0.37 –0.30 –0.59 –0.59 0.00 –0.10 –0.49
Aggression –0.15 –0.26 –0.22 –0.71 –0.23 –0.23 –1.06
Ulity* 0.82 0.70 0.18 –0.67 1.65 1.04 –0.01
Clinical trial rank** 1 3 2 3 1 3 2
–2.00
–1.50
–1.00
–0.50
0.00
0.50
1.00
1.50
2.00
2.50
3.00
(a)
(b)
   Preference weighted outcomes of AEDs by DCE -1 (excluding women with potenal to become pregnant)
Arm A:  Paral epilepsy  Arm B: Generalised and unclassified epilepsy     
lamotrigine gabapenn carbamazepine tompiramate lamotrigine topiramate valproate
Remission 2.05 1.63 2.05 1.77 2.15 2.24 2.57
Seizure reducon –0.04 –0.03 –0.03 –0.02 –0.03 –0.01 –0.03
Depression –0.30 –0.23 –0.19 –0.56 –0.22 –0.07 –0.04
Memory problems –0.38 –0.74 –0.47 –0.74 –0.12 –0.62 0.00
Foetal abnormality –0.53 –0.34 –1.14 –0.99 –0.53 –0.99 –2.53
Ulity* 0.79 0.29 0.23 –0.54 1.24 0.55 –0.02
Clinical trial rank** 1 3 2 3 3 2 1
-4.00
-3.50
-3.00
-2.50
-2.00
-1.50
-1.00
-0.50
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
   Preference weighted outcomes of AEDs by DCE -2 (women with potenal to become pregnant)
Arm A:  Paral epilepsy  Arm B: Generalised and unclassified epilepsy     
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The key strengths of our study are in meeting the recommended 
qualities of patient preference studies specified by the CDRH5: 
(i) Patient centeredness: the DCE measured patient preferences 
for outcomes. Furthermore, the study encompassed the views of 
both patients and physicians at appropriate stages of develop-
ing the DCE, to ensure the hypothetical task was relevant to the 
context of clinical decisions. (ii) Representativeness of the sample 
and generalizability of results: the study used an appropriate sam-
ple size in each clinically well- defined group; however, there may 
be limitations in generalizability because of the sampling. (iii) 
Capturing heterogeneity of patients’ preferences: we identified clin-
ically important subgroups a priori and tailored individual DCEs 
in response to heterogeneity in preferences at the qualitative 
phase. (iv) Established good research practices by recognized profes-
sional organizations: we adhered to good practice guidelines.14,32 
(v) Effective communication of benefit, harm, risk, and uncertainty: 
attribute levels were displayed as natural frequencies with picto-
graphs, as recommended.5 (vi) Minimal cognitive bias: cognitive 
interviewing was used to minimize framing effects and choices or-
dered randomly. (vii) Logical soundness: we demonstrated a high 
level of internal validity with a dominance test. (viii) Relevance: 
potential attributes identified from validated outcome measures, 
reduced systematically using a qualitative study and defined by 
clinically meaningful thresholds. (ix) Robustness of analysis of re-
sults: analysis adhered to good practice guidelines9,32 with uncer-
tainty represented by bootstrapped confidence intervals. (x) Study 
conduct: trained and experienced researchers interviewed patients, 
and the DCE questionnaire was verified by patients and health-
care professionals. (xi) Comprehension by study participants: robust 
application of cognitive interviews and questionnaire piloting to 
ensure face validity and optimal comprehension choice tasks.14
There were, however, limitations to our approach. Bias arising 
from patients self- selecting to complete the questionnaire will 
limit the generalizability of the results. We also acknowledge 
that although DCE is a recommended approach to benefit–risk 
assessment, other methods exist, including multicriteria deci-
sion analysis33 and health outcome modeling.8,34 Our methods 
highlighted differences in responses linked to the methods used. 
The ranking of single outcomes identified seizure remission as 
the most important, whereas the DCE identified that reductions 
in the risk of AEs were more highly valued than improvements 
in seizure control. Although ranking exercises do not consider 
trade- offs explicitly, DCEs benefit from capturing this to as-
sess the MAR for a given level of benefit. DCEs are inherently 
limited by the potential for patients’ stated preferences not re-
flecting their revealed preferences accurately and the cognitive 
burden placed on respondents, which increases rapidly with the 
number of attributes. Consequently, differences between stud-
ies in benefit and risk attributes are inevitable,28–31 although 
in mitigation, our study used a robust approach to attribute 
selection.5,14,32
In conclusion, our case study findings indicate that accounting 
for patient preferences, in addition to clinical variables, could lead 
to different treatment choices or regulatory decisions. The most 
substantive results for AEDs are that women of childbearing po-
tential show a clear preference for lamotrigine over valproate, prin-
cipally driven by a preference to avoid the risk of teratogenicity 
(major malformation rate, ≈11%19). This is despite clinical trial 
results showing valproate to be significantly more effective than 
lamotrigine in generalized onset seizures,17 and aligns with recom-
mendations from regulators.25,26
The study demonstrates how patients’ preference for treat-
ment benefits and risks can be incorporated into benefit–risk as-
sessments by obtaining quantitative evidence using a DCE. Our 
method represents a transparent and valid approach to examining 
a patient- oriented perspective in support of regulatory assessments 
of medicines.1 It also builds on previous research that highlighted 
that, although studies quantifying preferences may allow for formal 
evidence- based appraisal of benefit–risk values, more is required to 
ensure best practice and to develop methods that combined stated 
Figure 2 DCE, discrete choice experiment; FDA, US Food and Drug Administration. Adaptation of the FDA Benefit–Risk Framework, highlighting 
opportunities for consideration of patient- focused evidence across each dimension, and linking to methods described for stages 1, 2, and 3 in 
the context of antiepileptic drug assessment.
Benefit risk summary and assessment Paent-focused drug development
Dimension Evidence and 
uncertainty
Conclusions 
and reasons
Analysis of condion
Idenfying and measuring what ma	ers most to 
paents (e.g. findings of qualitave interviews, 
ranking exercises)
Current treatment opons
Defining therapeuc context for benefit-risk 
assessments (e.g. idenfying important harms and 
benefits)
Benefit
Integrang paent-reported outcomes and elicited 
preferences into benefit-risk assessments (e.g. DCE 
linked with clinical data)
Risk and risk management
Understanding and migang risks from paents’ 
perspecves (e.g. by understanding the trade-off 
between benefits and risks)
Stage 1
Stages 2 & 3
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Table 4 Summary of the stages involved in development of the case study
Stage Stage 1: benefit–risk outcome selection Stage 2: DCE
Stage 3: modeling- expected utility of 
alternative AEDs
Principal 
(supplementary) 
method
Interviews with patients Meeting with 
physicians 
(cognitive interviews 
with patients)
Web- based survey 
(pilot questionnaire)
Obtain observed 
data for outcomes
Calculate expected 
utility model
Aim To identify the outcomes 
of AEDs that are most 
important to patients and 
their priorities for these 
outcomes
To assess the 
plausibility of the 
benefit–risk 
outcomes selected 
by patients in stage 
1, for use in a DCE 
(to confirm the face 
validity of the 
highest rank 
outcomes in the 
format of a DCE)
To value the patient 
preferences for five 
benefit–risk 
outcomes of AEDs
Obtain trial data on 
outcome event 
rates for four 
alternative drugs for 
focal epilepsy 
(carbamazepine, 
lamotrigine, 
gabapentin, and 
topiramate) and 
three alternative 
drugs for 
generalized and 
unclassified 
epilepsy (valproate, 
lamotrigine, and 
topiramate)
Estimate the 
expected utility 
associated with each 
AED for both 
indications
Sample Adult patients with 
epilepsy recruited via 
three specialist neurology 
secondary and tertiary 
care referral centers in 
England (n = 41). 
Subgroups: patients with 
a recent diagnosis 
(3–12 months), patients 
with an established 
diagnosis (>12 months), 
and women of 
childbearing age 
(18–50 years)
Nine physicians 
responsible for 
prescribing AEDs to 
adults with epilepsy 
(a further 13 
patients from 
sampling frame 
used in stage 1)
Adult patients 
self- reporting as 
aged ≥18 years and 
diagnosed with 
epilepsy by a 
physician (n = 280). 
Subgroups: women 
self- identifying as 
being of 
childbearing 
potential and other 
responders 
(Epilepsy Action 
staff and 
volunteers, clinical 
and academic 
researchers, and 
members of the 
scientific advisory 
group)
SANAD clinical trial 
and Cochrane 
review of 
monotherapy 
treatment of 
epilepsy in 
pregnancy
Method Semistructured interview 
and ranking exercise: 
Which outcomes are 
most important to you? 
Rank your top four 
(highest = 4, lowest = 1). 
Analysis: Mean rank 
score per outcome by 
subgroup. Outputs: Most 
important outcomes from 
patients’ perspective
Group discussion 
and individual 
ranking exercises: 
Which outcomes are 
most important to 
you? Define the 
frequency and 
seriousness at 
which an adverse 
event becomes 
“clinically 
important.” 
Analysis: Mean rank 
score per outcome 
by time since 
patient diagnosis, 
early or established. 
Outputs: Most 
plausible outcomes 
from the 
prescribers’ 
perspective (think 
aloud experiment)
Random- effects 
logit model with 
1,000 bootstrap 
replications. 
Outputs: preference 
weights for 
outcomes, 
maximum 
acceptable risk of 
harm for a gain in 
benefit (Online: 
invitation to 
complete the 
questionnaire and 
supply comments)
Parameter 
uncertainty 
represented by 
drawing from β 
distributions for the 
number of events in 
the observed data. 
1,000 replications 
were simulated, and 
the confidence 
intervals were taken 
to be the 25th and 
975th percentile of 
the variable
Utility = Σ(β_
outcome*events). 
Confidence intervals 
generated from 
simulated preference 
and event data. 
Outputs: Total utility 
and rank order of 
AEDs by preference- 
weighted rank
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preferences and clinical data.35 Certainly, drug regulators will need 
to be cognizant of the evolving methods of preference- based bene-
fit–risk, including DCEs.36
METHODS
The study comprised three stages (Table 4): (i) identification of the most 
important outcomes of AED treatment using qualitative interviews and 
ranking exercises with patients and a focus discussion group meeting of 
physicians; (ii) elicitation of patient preferences for these outcomes using 
a DCE; and (iii) estimation of the expected utility associated with alter-
native AEDs by combining preference weights with data from a clinical 
trial.
Ethical approval was granted by the UK National Health Service 
Research (reference number: 11/NW/0191).
Stage 1: benefit–risk outcome selection
The first stage in the method was to identify patients’ most important 
outcomes of AED treatment for inclusion in the DCE. A qualitative 
study was designed according to good practice guidelines.14,32,37 All 
interviews were conducted in patients’ own homes, and consent was 
requested to audiotape record for subsequent transcription. Patients 
were asked to consider predefined treatment outcomes, which were 
categorized according to whether they were treatment benefits, adverse 
effects, or life impacts, and selected from clinical trials16,17 and val-
idated outcome measures.38–41 Patients were first asked to nominate 
any additional outcomes, on the basis of their own experiences, that they 
considered were missing from each category. Next, they were asked to se-
lect the outcomes that were most important to them from each category. 
Finally, considering all the outcomes they had selected, across the three 
categories, they were asked to choose their top four, and rank them in 
order of importance.
The face validity and plausibility of the 10 most important attributes 
overall were examined using cognitive interviews with patients and a meet-
ing with prescribing physicians. The meeting of physicians responsible for 
prescribing AEDs to adults with epilepsy was convened at the Walton 
Centre National Health Service Foundation Trust. Participants were first 
asked to rank the 10 treatment outcomes that patients had considered the 
most important. They then participated in semistructured discussions to 
share their practical experience of discussing treatment outcomes with 
patients and, in particular, their distinction between “adverse effects” and 
“life impacts” relating to AEDs. They were asked to independently record 
Stage Stage 1: benefit–risk outcome selection Stage 2: DCE
Stage 3: modeling- expected utility of 
alternative AEDs
Outcomes 
assessed at 
each stage
Benefits: reduction in 
seizure frequency, 
reduction in seizure 
severity
Adverse events: memory 
problems, depression, 
fetal abnormality, anger 
and aggression, 
headache, sleepiness 
and drowsiness, difficulty 
concentrating, weight 
gain, skin rash, dizziness, 
nervousness and/or 
agitation, tiredness 
Life impacts: limits ability 
to work in paid 
employment, reduces 
independence, negative 
impacts on relationships 
with family and/or 
friends, makes you feel 
less in control of the 
things that happen to 
you, limits hopes and 
plans for the future, limits 
social life and activities, 
increases the worry about 
having a seizure, causes 
problems with everyday 
memory and/or 
concentration, extent to 
which other people treat 
you like an inferior 
person, makes you feel 
more negative about 
yourself 
Patients could also 
self- nominate any 
outcome they considered 
to be missing
Benefits: reduction 
in seizure frequency 
Adverse events: 
memory problems, 
depression, fetal 
abnormality, anger 
and aggression, 
headache 
Life impacts: limits 
ability to work in 
paid employment, 
reduces 
independence, 
negative impacts on 
relationships with 
family and/or 
friends, makes you 
feel less in control 
of the things that 
happen to you, 
limits hopes and 
plans for the future
Benefits: remission, 
reduction in seizure 
frequency 
Adverse events: 
memory problems, 
depression, anger 
and aggression, 
fetal abnormality
Benefits: remission, 
reduction in seizure 
frequency 
Adverse events: 
memory problems, 
depression, anger 
and aggression, 
fetal abnormality
Benefits: remission, 
reduction in seizure 
frequency 
Adverse events: 
memory problems, 
depression, anger 
and aggression, fetal 
abnormality 
Total utility per AED
AED, antiepileptic drug; DCE, discrete choice experiment; SANAD, Standard vs. New Antiepileptic Drugs.
Table 4 (Continued)
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the frequency and seriousness at which an AE becomes a “clinically im-
portant” AE that required a change in treatment. For example, clinically 
important depression was described as “low mood which often affects ac-
tivities of daily life.” The purpose of this exercise was to ensure parity be-
tween DCE descriptions of treatment outcomes and clinically important 
AE data recorded in clinical trials,16,17 to ensure optimal integration of 
preferences with clinical evidence. Prescribers were also asked to draw on 
their experience of communicating benefit–risk to patients and to provide 
feedback on the formatting of the patient DCE questionnaire. Discussions 
were audiotape recorded, and ranking results were noted in workbooks 
that were self- completed during the session.
Stage 2: DCE
The DCE was conducted, analyzed, and reported according to good 
practice guidelines.32,42 The five treatment outcomes ranked highest 
by patients, and which were considered clinically plausible, were in-
cluded as attributes in the DCE. Each attribute was assigned two levels 
on the basis of data from a clinical trial16,17 and information on the risk 
of AED- related fetal abnormality available to patients on the Epilepsy 
Action charity website at the time of the survey. Levels represent the 
frequency of events observed in clinical trials and were presented in the 
questionnaire as a “1 in X people experience…”, supplemented with pic-
tograms that used a traffic light color coding for positive and negative 
effects.
The DCE consisted of eight binary choice scenarios (Figure S1), which 
asked: Which medication would you prefer? A partially dominant choice 
was used to test the internal validity of the DCE, in which “medication A” 
had a higher chance of remission and lower risk of AEs; therefore, it was 
assumed respondents would prefer this option.
Patient DCE questionnaire
Adults self- reporting as being aged ≥18 years and diagnosed as having 
epilepsy by a physician were eligible to complete the survey. Respondents 
were required to consent to participate in the study before they ac-
cessed the questionnaire, and there was no compensation for their time. 
Recruitment was via publicity from the charity, Epilepsy Action, an ad-
vertisement in local press, and posters in 113 National Health Service out-
patient clinics across England and Wales. The survey was implemented 
online (Snap Surveys, London, UK) between June and October 2013 and 
hosted by the Epilepsy Action website. Estimated completion time was 
30 minutes. Target sample size was a minimum of 63 respondents per 
DCE, based on each main effect level of interest being represented across 
the design at least 500 times.43 A random sample of 25% was directed 
to a DCE designed to compare patients’ with physicians’ preferences for 
pharmacogenetic testing prior treatment with carbamazepine, which is 
reported elsewhere.30 Remaining respondents were directed to one of 
the two DCEs reported herein via a series of filter questions (DCE- 2 for 
women of childbearing potential; DCE- 1 for everyone else).
The questionnaire was piloted in a convenience sample of Epilepsy 
Action staff and volunteers, clinical and academic research staff, physicians 
who agreed to be contacted after the focus group, and members of our 
scientific advisory group. These individuals provided feedback on aspects 
such as the phrasing of the attributes and the selection criteria for women 
of childbearing potential, which was changed from being defined by age to 
a single question that asked, “Is there any chance, however remote, that you 
may become pregnant in the future?”
Statistical analysis
Responses to the DCE were analyzed in STATA, version 13 (StataCorp 
LP, College Station, TX) using a random- effects logit model that allowed 
for multiple observations (eight binary choices) from the same respon-
dent.44 The regression model estimated preference weights for each at-
tribute that indicate the importance of attributes and the direction of 
effect. The coefficients (β) from the regression were used to calculate 
the MAR of an AE that respondents were willing to accept in exchange 
for a percentage point improvement in benefit (12- month remission) 
(Figure S2).
Confidence intervals (95%) were determined from 1000 bootstrap 
replications.
Stage 3: estimating the utility for a given AED
The expected utility model was parameterized using the preference 
weights elicited in the DCE and data on the number of events for each 
outcome assessed in the DCE, from the Standard vs. New Antiepileptic 
Drugs (SANAD) clinical trial of AEDs16,17 and from a meta- analysis 
of the effects of prenatal exposure to commonly prescribed AEDs on the 
Table 5 Clinical event data used to calculate preference weights and total utility by AED
Variable
Partial epilepsy Generalized and unclassified epilepsy
Carbamazepine Gabapentin Lamotrigine Topiramate Ref. Valproate Topiramate Lamotrigine Ref.
12- Month remission at year 
2 observation (PP)
44 35 44 38 16 55 48 46 17
Seizure reduction at year 2 
observationa
13 14 21 10 16 12 5 15 17
Clinically important adverse effects
Depression 2.23 2.79 3.58 6.70 16 0.44 0.88 2.64 17
Memory problems 3.35 5.31 2.75 5.31 16 0.00 4.42 0.88 17
Behavior/personality 
change/aggression
1.12 1.68 1.93 5.31 16 1.75 7.96 1.76 17
Major congenital malfor-
mation outcomes in the 
children of women 
receiving AED treatment 
while pregnant
4.93 1.47 2.31 4.28 19 10.93 4.28 2.31 19
Data are given as events per 100 patients.
AED, antiepileptic drug; PP, trial per- protocol analysis. aCalculated as the number of patients still receiving randomized drug at year 2 observation, minus the 
number of patients who had achieved 12- month remission at year 2 observation (based on PP).
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prevalence of congenital malformations in the child19 (Table 5). The β 
coefficients for each outcome (derived in stage 2) were multiplied by the 
corresponding clinical trial event rate and summed to estimate the total 
utility for each AED42 (Figure S2). The ranking of AEDs by total util-
ity was compared with ranking by time to treatment failure (because of 
inadequate seizure control or AEs), chosen to reflect the benefit–harm 
trade- off observed in the clinical trial.16,17
SUPPORTING INFORMATION 
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com). 
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